Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

1.0K
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.0K
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

1.4K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.4K
Activation of Integrins01:15

Activation of Integrins

5.2K
Integrins bind ligands and transmit information from outside the cell to inside or vice-versa through an "outside-in signaling" or "inside-out signaling."
In "outside-in signaling," external factors in the extracellular space bind to exposed ligand binding sites on integrins. This causes the inactive protein to undergo a conformational change to become active. Integrins are often clustered on the cell membrane. Repetitive and regularly spaced ligand binding...
5.2K
Integrins01:10

Integrins

5.7K
Animal and protozoan cells do not have cell walls to help maintain shape and provide structural stability. Instead, these eukaryotic cells secrete a sticky mass of carbohydrates and proteins into the spaces between adjacent cells. This network of proteins and molecules is called an extracellular matrix or ECM.
Some ECM proteins assemble into a basement membrane to which the remaining components adhere. Proteoglycans typically form the bulk of the ECM while fibrous proteins, like collagen,...
5.7K
Intracellular Signaling Affects Focal Adhesions01:17

Intracellular Signaling Affects Focal Adhesions

3.7K
Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
3.7K
Ophthalmic Drug Delivery Systems01:23

Ophthalmic Drug Delivery Systems

54
Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...
54

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Beyond Glucose: Palmitic Acid Influences VEGFA-VEGFR2 Angiogenic Signaling in Müller Glial Cells.

International journal of molecular sciences·2026
Same author

Acute anterior segment biometric effects of brimonidine assessed by swept source OCT supporting its use in managing visual disturbances.

Scientific reports·2026
Same author

GABA Receptor Activation in Müller Glia as a Molecular Switch for Controlling VEGF-A in the Retina.

ASN neuro·2026
Same author

Downregulation of TRPV4 and LRRC8A in Crystalline Lenses of Diabetic Patients May Contribute to Cataractogenesis.

Clinical ophthalmology (Auckland, N.Z.)·2025
Same author

Insights and advancements in molecular biology techniques in ophthalmology.

Experimental eye research·2025
Same author

From Neurotransmission to Retinal Pathophysiology: Unraveling the Role of GABA Receptors in Retinal Disease Progression.

Journal of neurochemistry·2025

Related Experiment Video

Updated: Feb 19, 2026

Author Spotlight: Development of a Method for Identifying Small Molecular Antagonists of β2 Integrin Activation
04:15

Author Spotlight: Development of a Method for Identifying Small Molecular Antagonists of β2 Integrin Activation

Published on: February 2, 2024

2.4K

Current Anti-Integrin Therapy for Ocular Disease.

Roberto Gonzalez-Salinas1, Luis F Hernández-Zimbrón1, Rosario Gulias-Cañizo1,2

  • 1a Research Department , Asociación para Evitar la Ceguera en México I.A.P , Mexico City , Mexico.

Seminars in Ophthalmology
|November 1, 2017
PubMed
Summary
This summary is machine-generated.

Anti-integrin therapies show promise for various ocular diseases. Clinical trials indicate these treatments can improve symptoms in conditions like dry eye and macular degeneration.

Keywords:
LFA-1integrinΑlβ2α4β1αvβ3

More Related Videos

Intravitreal Injections in the Ovine Eye
03:37

Intravitreal Injections in the Ovine Eye

Published on: July 5, 2022

4.1K
Dynamic Adhesion Assay for the Functional Analysis of Anti-adhesion Therapies in Inflammatory Bowel Disease
08:27

Dynamic Adhesion Assay for the Functional Analysis of Anti-adhesion Therapies in Inflammatory Bowel Disease

Published on: September 20, 2018

8.1K

Related Experiment Videos

Last Updated: Feb 19, 2026

Author Spotlight: Development of a Method for Identifying Small Molecular Antagonists of β2 Integrin Activation
04:15

Author Spotlight: Development of a Method for Identifying Small Molecular Antagonists of β2 Integrin Activation

Published on: February 2, 2024

2.4K
Intravitreal Injections in the Ovine Eye
03:37

Intravitreal Injections in the Ovine Eye

Published on: July 5, 2022

4.1K
Dynamic Adhesion Assay for the Functional Analysis of Anti-adhesion Therapies in Inflammatory Bowel Disease
08:27

Dynamic Adhesion Assay for the Functional Analysis of Anti-adhesion Therapies in Inflammatory Bowel Disease

Published on: September 20, 2018

8.1K

Area of Science:

  • Integrin biology and cell adhesion mechanisms.
  • Immunology and inflammatory pathways.
  • Ophthalmology and ocular disease treatment.

Background:

  • Integrins are key cell adhesion molecules involved in cell-matrix interactions and inflammation.
  • They are crucial in leukocyte function and inflammatory processes.
  • Understanding integrin roles is vital for developing targeted therapies.

Purpose of the Study:

  • To review current anti-integrin therapies for ocular conditions.
  • To assess ongoing clinical trials in ophthalmology.
  • To summarize the efficacy of integrin antagonists in eye diseases.

Main Methods:

  • Literature search of PubMed, CINAHL, and Embase databases.
  • Inclusion of MeSH terms related to integrin therapy and specific integrin subtypes (e.g., α4β1, αvβ3).
  • Analysis focused on Phase 2 and 3 clinical trials with at least six months follow-up.

Main Results:

  • Integrin antagonists demonstrated efficacy in improving signs and symptoms.
  • Positive outcomes were observed in dry eye disease, age-related macular degeneration, and diabetic macular edema.
  • Therapeutic potential also noted for vitreomacular traction.

Conclusions:

  • Anti-integrin therapy represents a promising treatment strategy for multiple ocular diseases.
  • Ongoing clinical trials are evaluating the full potential of these agents.
  • Further research is warranted to optimize integrin-targeted treatments in ophthalmology.